3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
12
Other hematologic neoplasm
5
Lymphoid
4
Gastrointestinal
4
Dermatologic
4
Plasma cell
3
Myeloid
2
Tumor-Agnostic
1
Thoracic
1
Other
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Interventions
Cyclophosphamide
58
Busulfan
47
fludarabine phosphate
45
Cyclosporine
34
Mycophenolic Acid
31
Whole-Body Irradiation
29
Peripheral Blood Stem Cell Transplantation
29
fludarabine
27
Antilymphocyte Serum
27
Tacrolimus
26
Methotrexate
25
Melphalan
25
Filgrastim
20
Radiotherapy
19
Darbepoetin alfa
19
Cytarabine
19
Cord Blood Stem Cell Transplantation
18
Epoetin Alfa
17
Granulocyte Colony-Stimulating Factor
14
Methylprednisolone
13
thymoglobulin
10
Thiotepa
9
Etoposide
9
Alemtuzumab
9
eltrombopag
8
Stem Cell Transplantation
8
olaparib
7
sargramostim
6
hetrombopag
6
Rituximab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tablets
×
Classical hematology
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled